Savara IncSVRA
Price$5.04

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$139.3MTTM through 30 Jun 2026
Free Cash Flow -$110.7MTTM through 30 Jun 2026

Margins

Current

Returns

-21.2%ROE
-16.8%ROA

Balance Sheet Health

Debt / Equity0.17x
Current Ratio13.47x
Net Debt-$11.7Mnet cash position
Cash & Equivalents$41.8M

Quality Metrics

Altman Z-Score7.02
Piotroski F-Score1 / 9
Earnings-Beat Rate0.0%

Multi-Year Trend

Revenue
'19'20
FY2020: $257K
Diluted EPS-$0.58TTM
'21'22'23'24'25
FY2025: $-0.53

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Specialty Pharmaceuticals$0
View details

The FDA has set a PDUFA target action date of November 22, 2026. Regulatory decisions in the UK and EU are expected in Q4 2026 and Q1 2027, respectively.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.